These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 28664749)

  • 1. The age at onset in Multiple Sclerosis is associated with patient's prognosis.
    Cierny D; Lehotsky J; Hanysova S; Michalik J; Kantorova E; Sivak S; Kurca E; Dobrota D; Jesenska L
    Bratisl Lek Listy; 2017; 118(6):374-377. PubMed ID: 28664749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T2 lesions and rate of progression of disability in multiple sclerosis.
    Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
    Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The HLA-DRB1 and HLA-DQB1 alleles are associated with multiple sclerosis disability progression in Slovak population.
    Čierny D; Lehotský J; Kantorová E; Sivák Š; Javor J; Kurča E; Dobrota D; Michalik J
    Neurol Res; 2018 Jul; 40(7):607-614. PubMed ID: 29619906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between onset age and disability in multiple sclerosis patients studied using MSSS and a progression model.
    Ramachandran S; Strange RC; Jones PW; Kalra S; Nayak D; Hawkins CP
    Mult Scler Relat Disord; 2014 Sep; 3(5):593-9. PubMed ID: 26265271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural history of multiple sclerosis: a unifying concept.
    Confavreux C; Vukusic S
    Brain; 2006 Mar; 129(Pt 3):606-16. PubMed ID: 16415308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis.
    Gava G; Bartolomei I; Costantino A; Berra M; Venturoli S; Salvi F; Meriggiola MC
    Fertil Steril; 2014 Jul; 102(1):116-22. PubMed ID: 24794311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
    Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arylsulfatase a gene polymorphisms in relapsing remitting multiple sclerosis: genotype-phenotype correlation and estimation of disease progression.
    Baronica KB; Mlinac K; Ozretić D; Vladić A; Bognar SK
    Coll Antropol; 2011 Jan; 35 Suppl 1():11-6. PubMed ID: 21648305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunlight exposure and sun sensitivity associated with disability progression in multiple sclerosis.
    D'hooghe MB; Haentjens P; Nagels G; Garmyn M; De Keyser J
    Mult Scler; 2012 Apr; 18(4):451-9. PubMed ID: 21952096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year prognosis in multiple sclerosis: a better outcome in relapsing-remitting patients but not in primary progressive patients.
    Kerbrat A; Hamonic S; Leray E; Tron I; Edan G; Yaouanq J;
    Eur J Neurol; 2015 Mar; 22(3):507-e35. PubMed ID: 25515927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Redefining the Multiple Sclerosis Severity Score (MSSS): The effect of sex and onset phenotype.
    Zhou Y; Claflin SB; Stankovich J; van der Mei I; Simpson S; Roxburgh RH; Kalincik T; Blizzard L; Lugaresi A; Alroughani R; Sajedi SA; Butzkueven H; Pucci E; Spitaleri D; Granella F; Cristiano E; Yamout B; Hughes S; Gouider R; Sánchez Menoyo JL; Olascoaga J; McGuigan C; Shaw C; Kermode AG; Kasa K; Al-Harbi T; Altintas A; Laureys G; Fragoso Y; Hardy TA; Csepany T; Sirbu CA; Decoo D; Sas A; Alvarez-Cermeño JC; Kotkata K; Millán-Pascual J; Taylor BV
    Mult Scler; 2020 Nov; 26(13):1765-1774. PubMed ID: 31668127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients.
    Lanzillo R; Di Somma C; Quarantelli M; Ventrella G; Gasperi M; Prinster A; Vacca G; Pivonello C; Orefice G; Colao A; Morra VB
    Eur J Neurol; 2011 Dec; 18(12):1402-6. PubMed ID: 21585623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal follow-up of "benign" multiple sclerosis at 20 years.
    Sayao AL; Devonshire V; Tremlett H
    Neurology; 2007 Feb; 68(7):496-500. PubMed ID: 17296915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disability progression in multiple sclerosis: a Tunisian prospective cohort study.
    Hentati E; Ben Sassi S; Nabli F; Mabrouk T; Zouari M; Hentati F
    Neurol Sci; 2018 May; 39(5):879-884. PubMed ID: 29476286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prognostic value of initial relapses on the evolution of disability in patients with relapsing-remitting multiple sclerosis.
    Binquet C; Quantin C; Le Teuff G; Pagliano JF; Abrahamowicz M; Moreau T
    Neuroepidemiology; 2006; 27(1):45-54. PubMed ID: 16825794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D is associated with degree of disability in patients with fully ambulatory relapsing-remitting multiple sclerosis.
    Thouvenot E; Orsini M; Daures JP; Camu W
    Eur J Neurol; 2015 Mar; 22(3):564-9. PubMed ID: 25530281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score.
    Guerrero AL; Laherrán E; Gutiérrez F; Martín-Polo J; Iglesias F; Alcázar C; Peralta J; Rostami P
    Acta Neurol Scand; 2008 Jan; 117(1):21-5. PubMed ID: 17883422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
    Roxburgh RH; Seaman SR; Masterman T; Hensiek AE; Sawcer SJ; Vukusic S; Achiti I; Confavreux C; Coustans M; le Page E; Edan G; McDonnell GV; Hawkins S; Trojano M; Liguori M; Cocco E; Marrosu MG; Tesser F; Leone MA; Weber A; Zipp F; Miterski B; Epplen JT; Oturai A; Sørensen PS; Celius EG; Lara NT; Montalban X; Villoslada P; Silva AM; Marta M; Leite I; Dubois B; Rubio J; Butzkueven H; Kilpatrick T; Mycko MP; Selmaj KW; Rio ME; Sá M; Salemi G; Savettieri G; Hillert J; Compston DA
    Neurology; 2005 Apr; 64(7):1144-51. PubMed ID: 15824338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses and progression of disability in multiple sclerosis.
    Confavreux C; Vukusic S; Moreau T; Adeleine P
    N Engl J Med; 2000 Nov; 343(20):1430-8. PubMed ID: 11078767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.